Early national dissemination of abiraterone and enzalutamide for advanced prostate cancer in Medicare Part D.
Caram M, Borza T, Min H, Griggs J, Miller D, Hollenbeck B, Mukherjee B, Skolarus T. Early national dissemination of abiraterone and enzalutamide for advanced prostate cancer in Medicare Part D. Journal Of Clinical Oncology 2017, 35: 35-35. DOI: 10.1200/jco.2017.35.8_suppl.35.Peer-Reviewed Original ResearchAdvanced prostate cancerHospital referral regionsProstate cancerProvider specialtyAdvanced prostate cancer treatmentProstate cancer incidenceProstate cancer treatmentMedicare Part DEnzalutamide prescriptionsFood & Drug AdministrationMedicare Part D dataEnzalutamideMinority of providersAbirateroneMedical oncologistsOral medicationsMedical oncologyEarly disseminationTreated menPart D dataCancer incidenceDrug AdministrationCancer treatmentMultilevel regression modelsPart D
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply